X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4656) 4656
Book Review (1171) 1171
Publication (469) 469
Newsletter (67) 67
Conference Proceeding (19) 19
Book Chapter (18) 18
Magazine Article (14) 14
Newspaper Article (7) 7
Dissertation (6) 6
Book / eBook (2) 2
Reference (2) 2
Government Document (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3863) 3863
humans (3811) 3811
thalidomide - analogs & derivatives (2873) 2873
thalidomide (1989) 1989
thalidomide - therapeutic use (1919) 1919
male (1744) 1744
female (1604) 1604
oncology (1488) 1488
multiple myeloma - drug therapy (1347) 1347
hematology (1331) 1331
middle aged (1331) 1331
aged (1281) 1281
thalidomide - administration & dosage (1244) 1244
lenalidomide (1202) 1202
multiple myeloma (1065) 1065
treatment outcome (952) 952
thalidomide - adverse effects (923) 923
antineoplastic combined chemotherapy protocols - therapeutic use (912) 912
adult (889) 889
bortezomib (811) 811
thalidomide - pharmacology (766) 766
antineoplastic agents - therapeutic use (763) 763
animals (749) 749
therapy (631) 631
aged, 80 and over (565) 565
cancer (534) 534
care and treatment (505) 505
dexamethasone - administration & dosage (495) 495
pharmacology & pharmacy (486) 486
dexamethasone (457) 457
chemotherapy (446) 446
multiple-myeloma (439) 439
stem-cell transplantation (424) 424
drug therapy (389) 389
angiogenesis inhibitors - therapeutic use (380) 380
abridged index medicus (369) 369
survival (367) 367
multiple myeloma - pathology (366) 366
immunologic factors - therapeutic use (363) 363
antineoplastic combined chemotherapy protocols - adverse effects (353) 353
research (353) 353
mice (349) 349
medicine & public health (341) 341
angiogenesis (325) 325
recurrence (324) 324
disease-free survival (295) 295
hematology, oncology and palliative medicine (295) 295
prognosis (292) 292
analysis (290) 290
clinical trials as topic (290) 290
multiple myeloma - therapy (285) 285
antineoplastic agents - adverse effects (284) 284
myelodysplastic syndromes - drug therapy (283) 283
multiple myeloma - mortality (268) 268
angiogenesis inhibitors (266) 266
plus dexamethasone (265) 265
dose-response relationship, drug (263) 263
antineoplastic agents - pharmacology (260) 260
transplantation (254) 254
boronic acids - therapeutic use (247) 247
pyrazines - therapeutic use (247) 247
health aspects (246) 246
necrosis-factor-alpha (230) 230
immunosuppressive agents - therapeutic use (226) 226
drug therapy, combination (224) 224
article (222) 222
antineoplastic combined chemotherapy protocols - administration & dosage (221) 221
myelodysplastic syndromes (220) 220
analogs (217) 217
tnf-alpha (216) 216
combination (215) 215
clinical trials (214) 214
disease progression (214) 214
expression (214) 214
efficacy (213) 213
remission induction (213) 213
antineoplastic agents - administration & dosage (210) 210
dexamethasone - therapeutic use (209) 209
cell line, tumor (208) 208
trial (208) 208
cells (207) 207
boronic acids - administration & dosage (203) 203
immunology (203) 203
pyrazines - administration & dosage (202) 202
retrospective studies (202) 202
pomalidomide (195) 195
survival analysis (195) 195
drug administration schedule (194) 194
thalidomide analogs (194) 194
apoptosis (192) 192
myelodysplastic syndromes - genetics (191) 191
risk factors (189) 189
survival rate (189) 189
multiple myeloma - diagnosis (185) 185
myeloma (183) 183
follow-up studies (178) 178
medicine, general & internal (178) 178
dosage and administration (177) 177
in-vitro (177) 177
chromosome deletion (175) 175
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4519) 4519
Japanese (97) 97
French (37) 37
German (36) 36
Chinese (27) 27
Spanish (19) 19
Czech (18) 18
Polish (5) 5
Danish (2) 2
Hungarian (2) 2
Portuguese (2) 2
Italian (1) 1
Korean (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE COMMUNICATIONS, ISSN 2041-1723, 04/2019, Volume 10, Issue 1, pp. 1911 - 1911
Journal Article
Journal of Enzyme Inhibition and Medicinal Chemistry, ISSN 1475-6366, 01/2019, Volume 34, Issue 1, pp. 1259 - 1270
Pyrazolylphthalimide derivative 4 was synthesized and reacted with different reagents to afford the target compounds imidazopyrazoles 5-7, pyrazolopyrimidines... 
molecular modeling study | drug-likeness | Phthalimide | antimicrobial and anticancer activities | DNA gyrase B | VEGFR-2 | CHEMISTRY, MEDICINAL | MOIETY | BIOCHEMISTRY & MOLECULAR BIOLOGY | THALIDOMIDE | DISCOVERY | HETEROCYCLIC SYNTHESIS | IN-VITRO | PYRAZOLE | ANTIBACTERIAL ACTIVITY | DRUGS | INHIBITORS | DERIVATIVES
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 08/2019, Volume 176, pp. 419 - 430
Lenalidomide and its analogs have exhibited extensive anti-tumor, anti-inflammatory and immunomodulatory properties in pharmaceutical research. In this work, a... 
Thioether | Anti-Tumor | Structural modification | Lenalidomide | DEXAMETHASONE | CHEMISTRY, MEDICINAL | NATURAL-KILLER-CELL | THALIDOMIDE | SULFONE | IDENTIFICATION | POTENT INHIBITORS | POMALIDOMIDE | DEGRADATION | T-CELLS | MODULATION | Research institutes | Analysis | Cells | Tumors
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2019, Volume 9, Issue 1, pp. 1 - 11
Thalidomide is widely used for several diseases; however, it causes malformations in embryos exposed during pregnancy. The complete understanding of the... 
LIMB | VARIANTS | MULTIDISCIPLINARY SCIENCES | PHENOTYPE | EMBRYOPATHY | MUTATIONS | ROBERTS-SYNDROME | IDENTIFICATION | MEMBER | Pregnancy | Teratogenesis | Gene regulation | Stem cells | Genomes | Gene expression | Embryos | Thalidomide | Heart diseases | Coronary artery disease | Pluripotency | Index Medicus
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 08/2019, Volume 856, pp. 172409 - 172409
EGF receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used as a standard therapy in non-small cell lung cancer (NSCLC) patients with EGFR... 
EGFR-TKI resistant | p-EGFR | Gefitinib | Thalidomide | Lung cancer | GROWTH-FACTOR-RECEPTOR | ANGIOGENESIS | TYROSINE KINASE | ACQUIRED-RESISTANCE | COMBINATION | CELL LUNG-CANCER | PHASE-II TRIAL | IN-VITRO | INHIBITION | LENALIDOMIDE | PHARMACOLOGY & PHARMACY
Journal Article
by Won, HR and Lee, DH and Yeon, SK and Ryu, HW and Kim, GW and Kwon, SH
INTERNATIONAL JOURNAL OF ONCOLOGY, ISSN 1019-6439, 08/2019, Volume 55, Issue 2, pp. 499 - 512
Nonselective histone deacetylase (HDAC) inhibitors have therapeutic effects, but exhibit dose-limiting toxicities in patients with multiple myeloma (MM). The... 
CELLS | multiple myeloma | DEXAMETHASONE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | COMBINATION | HDAC6-selective inhibitor | CEREBLON EXPRESSION | HDAC6 | IN-VITRO | ONCOLOGY | LENALIDOMIDE | combination therapy | HISTONE DEACETYLASE INHIBITORS | immunomodulatory drug
Journal Article
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 08/2019, Volume 123, Issue 2, pp. 158 - 165
Chronic itch can be a debilitating, unrelenting symptom. Over the years, we have advanced our knowledge about immune-mediated itch (eg, atopic dermatitis) and... 
BRACHIORADIAL PRURITUS | EFFICACY | ALLERGY | DOUBLE-BLIND | HEMODIALYSIS-PATIENTS | PROTEIN-COUPLED RECEPTORS | TOXIN TYPE-A | UREMIC PRURITUS | NOTALGIA PARESTHETICA | CHRONIC PRURITUS | THALIDOMIDE | IMMUNOLOGY | Index Medicus
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 08/2019, Volume 136, pp. 104937 - 104937
Thalidomide (TLD) is used to treat erythema nodosum leprosum (ENL), multiple myeloma, aphthous ulceration and wasting syndrome in HIV patients. The API can be... 
Thalidomide | Dissolution | Pharmacokinetic | Polymorphism | TRANSIT | PHYSIOLOGICAL-PARAMETERS | ALPHA | RELEASE | DISPOSITION | MICRODIALYSIS | PHARMACOKINETICS | FORMULATIONS | PHARMACOLOGY & PHARMACY | MEAN DISSOLUTION TIME | BLOOD
Journal Article
by Vu, BD and Ba, NMH and Phan, DC
ORGANIC PROCESS RESEARCH & DEVELOPMENT, ISSN 1083-6160, 07/2019, Volume 23, Issue 7, pp. 1374 - 1377
We report a simple and facile procedure for the preparation of thalidomide in two steps with a high overall yield (56%). The preparation was composed of a... 
leprosy | multiple myeloma | N-phthaloyl-DL-glutamic anhydride | thalidomide | ANALOGS | CHEMISTRY, ORGANIC | CHEMISTRY, APPLIED | rheumatoid arthritis | EFFICIENT | neoplastic diseases
Journal Article
Current Eye Research, ISSN 0271-3683, 07/2019, Volume 44, Issue 7, pp. 806 - 812
Purpose: To evaluate the efficacy of polytetrafluoroethylene/polylactide-co-glycolide (PTFE/PLGA) laminate containing sustained-release thalidomide for delayed... 
strabismus | thalidomide | Adjustable | polylactide-co-glycolide | polytetrafluoroethylene
Journal Article
Journal of Heterocyclic Chemistry, ISSN 0022-152X, 07/2019, Volume 56, Issue 7, pp. 1946 - 1952
A series of novel alicyclic oxalamide derivatives were synthesized by the reaction of the N‐alicyclic secondary amine analogs with the intermediates obtained... 
CHEMISTRY, ORGANIC | THALIDOMIDE | Analysis | Cells | Cytokines | Aminophenol | Hazards | Derivatives | Macrophages | Chemical synthesis | In vitro methods and tests | Thalidomide
Journal Article
Immunology Letters, ISSN 0165-2478, 07/2019, Volume 211, pp. 41 - 48
Although immunomodulatory drugs (IMiDs) were originally developed as anti-inflammatory drugs, they are effective for multiple myeloma. In order to gain further... 
Lenalidomide | Dendritic cell | IMiDs | HIGH-LEVEL | TARGET | CAPACITY | INTERLEUKIN-12 | THALIDOMIDE | IMMUNOLOGY | IL-12 PRODUCTION | DIFFERENTIATION | DERIVATIVES | EXPRESSION | PROMOTES | Anti-inflammatory drugs | Dendritic cells | Multiple myeloma | Interferon | DNA binding proteins | T cells | Protein binding
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 07/2019, Volume 29, Issue 13, pp. 1555 - 1564
Proteolysis targeting chimeras (PROTACs) are heterobifunctional compounds with molecular weights and other properties that lie outside the classic... 
Degradation | Oral bioavailability | Absorption | Beyond rule-of-five | PROTACs | bRo5 | Proteolysis targeting chimeras | DESIGN | CHEMISTRY, MEDICINAL | DRUG DISCOVERY | CHEMISTRY, ORGANIC | THALIDOMIDE | BROMODOMAIN | SOLUBILITY | PREDICTION | INDUCED PROTEIN-DEGRADATION | INHIBITION | RULE | KNOCKDOWN
Journal Article